Nuclear Medicine and Immunology 2021
DOI: 10.1007/978-3-030-81261-4_14
|View full text |Cite
|
Sign up to set email alerts
|

Radiolabeled Antibodies for Cancer Radioimmunotherapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 355 publications
0
2
0
Order By: Relevance
“…It is often found alongside CD19 and CD20 on the surface of hyperactivated B cells in autoimmune diseases. Consequently, Medimmune (a parent company of AstraZeneca) has developed some therapeutic approaches, including naked antibodies [132], antibody-drug conjugates [133], radioimmunoconjugate antibodies [134], bispecific antibodies [135], and trispecific antibodies [136]. Moxetumomab pasudotox is a murine mAb conjugated with a toxic fragment of Pseudomonas exotoxin A that specifically targets CD22.…”
Section: Cd22mentioning
confidence: 99%
“…It is often found alongside CD19 and CD20 on the surface of hyperactivated B cells in autoimmune diseases. Consequently, Medimmune (a parent company of AstraZeneca) has developed some therapeutic approaches, including naked antibodies [132], antibody-drug conjugates [133], radioimmunoconjugate antibodies [134], bispecific antibodies [135], and trispecific antibodies [136]. Moxetumomab pasudotox is a murine mAb conjugated with a toxic fragment of Pseudomonas exotoxin A that specifically targets CD22.…”
Section: Cd22mentioning
confidence: 99%
“…For radiotherapeutics, patient dosing is constrained based on dosimetry to ensure that tolerance limits for normal tissues are not exceeded. Compared with radiolabeled antibodies that may confer significant hematological toxicity [ 70 ], the kidneys are often cited as potential dose-limiting organs for peptides and peptidomimetics, which have emerged as preferred choices for radiopharmaceutical development. Cleavable linkers act as pharmacokinetic modifiers to mitigate radiation-induced nephrotoxicity.…”
Section: Perspective and Summarymentioning
confidence: 99%